BETTER NUMBERS: Johnson & Johnson's fourth-quarter net income jumped, mainly because of big charges a year ago. It made $2.57 billion, or 91 cents per share, on revenue of $17.56 billion. It expects 2013 earnings per share of $5.35 to $5.45.
ONGOING TROUBLES: Some consumer health products included in J&J's 30-plus recalls since 2009 still won't be back in stores this year, and consumer sales dipped again.
POSSIBLE SALE: J&J is mulling the sale or spinoff of its Ortho Clinical Diagnostics business, which makes equipment and supplies for detecting and diagnosing diseases.